Although these results are derived from animal models of neurological disorders such as PD and stroke, which do not directly replicate the pathophysiology of DOC, they highlight the potential of saxagliptin and other incretin-based medications to modulate monoaminergic systems that are also implicated in DOC. The gene discussed is GCG; the disease is ichthyosis.